Get the Stockscreener App
0.9999
3.80%
0.0366
After Hours:
1.05
0.0501
+5.01%
Jaguar Health Inc stock is traded at $0.9999, with a volume of 96,080.
It is up +3.80% in the last 24 hours and down -66.78% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
See More
Previous Close:
$0.9633
Open:
$0.9701
24h Volume:
96,080
Relative Volume:
0.96
Market Cap:
$4.91M
Revenue:
$29.57M
Net Income/Loss:
$-34.68M
P/E Ratio:
-0.00141
EPS:
-708.7214
Net Cash Flow:
$-7.58M
1W Performance:
-20.96%
1M Performance:
-66.78%
6M Performance:
-95.54%
1Y Performance:
-98.60%
1-Day Range:
$0.91
$1.0199
1-Week Range:
$0.91
$1.3596
52-Week Range:
$0.91
$84.32
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.9999 | 4.73M | 29.57M | -34.68M | -7.58M | -708.72 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health Inc (JAGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jaguar Health Inc (JAGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jaguar Health, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID) - ACCESS Newswire
TradingKey - TradingKey
Jaguar Health (NASDAQ: JAGX) puts major dilution and incentive plan votes to investors - Stock Titan
Jaguar Health Inc (JAGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jaguar Health (JAGX) Secures Compassionate Use for Crofelemer in EU - GuruFocus
Jaguar Reports Up to 48% Lower Weekly Support in One MVID Patient - Stock Titan
Jaguar Health (JAGX) Registration filing Summary - Quartr
Jaguar Health Company Profile & Introduction - Moomoo
JAGUAR HEALTH INC (JAGX) Stock Chart - ChartMill
Form S-1 Jaguar Health Inc For: 16 July By Investing.com - Investing.com South Africa
Enterprise value to EBIT forward of Jaguar Health, Inc. – FWB:1JA1 - TradingView
Jaguar Health (NASDAQ: JAGX) plans 5.5M-share resale registration - Stock Titan
Jaguar Health (NASDAQ: JAGX) details 40.8M-share, $40M equity line - Stock Titan
Jaguar Health | S-1: General form for registration of securities under the Securities Act of 1933 - Moomoo
Jaguar Health Napo And Alivus Enter New Manufacturing And Supply Agreement For CrofelemerSEC Filing - TradingView
Jaguar Health Extends Crofelemer Supply With Alivus Through 2029, Adds Minimum Purchase Commitments - TradingView
Jaguar Health (NASDAQ: JAGX) signs new crofelemer manufacturing pact - Stock Titan
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program - ACCESS Newswire
MSN Money - MSN
Jaguar Health (JAGX) Lytham Partners Fall 2025 Investor Conference Summary - Quartr
Jaguar Health (JAGX) Proxy filing Summary - Quartr
Price to book forward of Jaguar Health, Inc. – FWB:1JA1 - TradingView
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health - ACCESS Newswire
Jaguar Health stock and its path in specialty pharma. Investors weigh volatile moves - ad-hoc-news.de
Jaguar Health (JAGX) Slides 7.6% as Selling Pressure Tests Key Support ZoneCalendar Spread Trade - dars.gov.et
JAGXJaguar Health Inc Latest SEC Filings - Finviz
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th - ACCESS Newswire
Jaguar Health, Inc. Files 8-K Report on July 1, 2026 – Key Company Information & SEC Disclosure Details - Minichart
Jaguar Health Inc. Q1 2026 Earnings: EPS Falls Far Below Estimates, Stock Edges Higher Despite No Revenue - dars.gov.et
Enterprise value to revenue forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health Completes Conversion of Series O Preferred - TipRanks
Jaguar Health (JAGX) completes Series O preferred stock conversion to common shares - Stock Titan
Jaguar Health Inc. (JAGX) Holds Steady at $2.96 as Stock Consolidates Near Key LevelsTriple EMA - dars.gov.et
Jaguar Health (JAGX) Showcases Crofelemer Data at ESPGHAN Conference - GuruFocus
Jaguar Health reports crofelemer data for rare pediatric diseases By Investing.com - Investing.com Nigeria
Jaguar Health reports crofelemer data for rare pediatric diseases - Investing.com
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) - ACCESS Newswire
Jaguar Health says crofelemer cut one child's support needs by 48% - Stock Titan
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders - ACCESS Newswire
Enterprise value to EBIT forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
JAGX Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock Rallies Despite SurpriseShare Dilution Risk - dars.gov.et
Price to earnings forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Price to earnings forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Price to book forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Enterprise value to revenue forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Jaguar Health shares after reverse split, small-cap biotech stock in the OTC market spotlight - AD HOC NEWS
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - GlobeNewswire Inc.
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):